Adversarial Injection · Ramucirumab (Cyramza; IMC-1121B; CAS 947687-13-0; MW ~147 kDa fully human IgG1κ; IV infusion; anti-VEGFR-2 [KDR; FLK-1; CD309; VEGF RECEPTOR 2; CHROMOSOME 4q12; 1356-AA; ~230 kDa RTK] fully human monoclonal antibody; DAR 0 [unconjugated]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; VEGFR-2 [KDR; FLK-1; CD309; VEGF RECEPTOR 2; CHROMOSOME 4q12; 1356-AA; ~230 kDa (SDS-PAGE apparent; heavily glycosylated; ECD carries 11 N-glycosylation sites); 7 ECD IMMUNOGLOBULIN-LIKE (Ig-LIKE) DOMAINS: D1-D7; PRIMARY VEGF-A SIGNALING RECEPTOR (VEGFR-1 [FLT1] ACTS AS DECOY; VEGFR-3 [FLT4] LYMPHANGIOGENESIS); D2-D3 JUNCTION: PRIMARY VEGF-A BINDING SITE (VEGF-A KD ~1 nM; VEGF-C KD ~200 nM; VEGF-D KD ~200 nM); D4-D7: RECEPTOR DIMERIZATION INTERFACE + TRANSMEMBRANE + JUXTAMEMBRANE + KINASE [Y1054/Y1059 ACTIVATION LOOP; Y1175 → PLC-γ; Y1214 → Nck → p38 MAPK]; RAMUCIRUMAB BINDS D2-D3 JUNCTION → STERICALLY PREVENTS VEGF-A/-C/-D BINDING → PREVENTS VEGFR-2 HOMO/HETERODIMERIZATION (VEGFR-2/VEGFR-1; VEGFR-2/VEGFR-3; VEGFR-2/NRP1) → NO PHOSPHORYLATION → NO VEGF-AXIS ANGIOGENESIS; RECEPTOR-TARGETING [VEGFR-2] COMPLEMENTS LIGAND-TARGETING [BEVACIZUMAB VEGF-A]; FULLY HUMAN IgG1 (PHAGE DISPLAY LIBRARY; KD ~0.07 nM VEGFR-2 ECD; NO HACA]; FIRST ANTI-VEGFR-2 ANTIBODY EVER; REGARD mOS 5.2 MO; BLA 125477 APR 2014) · Attack #748

Ramucirumab (Anti-VEGFR-2 Fully Human IgG1κ MAb; Cyramza; IMC-1121B; CAS 947687-13-0; Eli Lilly and Company [Indianapolis IN; BLA 125477 holder; ImClone IMC-1121B origin → phage display fully human IgG1]; MECHANISM: FIRST ANTI-VEGFR-2 [KDR; FLK-1; CD309; VEGF RECEPTOR 2; CHROMOSOME 4q12; 1356-AA ~230-kDa RTK; 7 Ig-LIKE ECD DOMAINS (D1-D7); PRIMARY VEGF-A SIGNALING RECEPTOR; D2-D3 JUNCTION: VEGF-A/VEGF-C/VEGF-D BINDING; KD VEGF-A ~1 nM; Y1054/Y1059 KINASE ACTIVATION LOOP; Y1175 → PLC-γ → PKC → ERK [ENDOTHELIAL PROLIFERATION]; Y1214 → Nck → p38 MAPK [ENDOTHELIAL MIGRATION]; eNOS (Ser1177 phosphorylation via AKT → NO → VASODILATION + PERMEABILITY); RAMUCIRUMAB D2-D3 EPITOPE: Lys247-Arg254 / Lys286-Lys294 (D2-D3 junction loop; unique 3D epitope; KD ~0.07 nM fully human IgG1; >14× TIGHTER THAN VEGF-A KD ~1 nM → COMPETITIVE DISPLACEMENT OF VEGF-A/C/D; BLOCKS VEGFR-2 HOMO/HETERODIMERIZATION → NO TYROSINE AUTOPHOSPHORYLATION → COMPLETE VEGF-SIGNALING AXIS SHUTDOWN; RECEPTOR-TARGETING ANTIANGIOGENESIS: DISTINCT FROM BEVACIZUMAB [LIGAND VEGF-A TARGETING; CAN BE BYPASSED BY VEGF-C/D UPREGULATION → VEGFR-3 LYMPHANGIOGENESIS ESCAPE]; RAMUCIRUMAB BLOCKS VEGFR-2 DIRECTLY → NO VEGF-C/-D ESCAPE FOR VEGFR-2 SIGNALING; FULLY HUMAN (PHAGE DISPLAY LIBRARY; NO MURINE VH/VL; HAHA RATE <0.1%); NO COMPLEMENT-ACTIVATING IgG1 Fc EFFECTOR (NO ADCC; VEGFR-2 NOT ON B-CELLS; RAMUCIRUMAB ANTI-TUMOR SOLELY VIA VEGFR-2 BLOCKADE + VASCULAR EFFECTS)] ANTIBODY EVER FDA APPROVED; REGARD: mOS 5.2 vs 3.8 MO (HR 0.776; p=0.047) GASTRIC/GEJ SINGLE-AGENT 2ND LINE; BLA 125477 APRIL 21 2014) — Eli Lilly and Company Indianapolis IN (BLA 125477 holder; Cyramza developer; ImClone IMC-1121B phage display origin → Lilly acquisition 2008), Lonza Biologics Inc Portsmouth NH (fully human IgG1 ramucirumab manufacturing; VEGFR-2 antibody CHO bioreactor), and MD Anderson Cancer Center Houston TX (REGARD/RAINBOW enrollment; gastric/GEJ ramucirumab administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST VEGFR-2 RECEPTOR ANTIBODY EVER + REGARD mOS 5.2 MO: AI Prompt Injection via EHS Monitor Report AI

Ramucirumab (CAS 947687-13-0; NIOSH HD Category 1) is the first anti-VEGFR-2 (KDR; FLK-1; CD309; VEGF receptor 2; chromosome 4q12) fully human IgG1κ monoclonal antibody ever FDA approved, targeting the VEGF receptor directly rather than the VEGF-A ligand (complementary mechanism to bevacizumab), establishing the 165th mechanism class in the Glyphward adversarial portfolio. Originally developed by ImClone Systems (IMC-1121B; phage display fully human antibody library) and obtained by Eli Lilly in the 2008 $6.5 billion ImClone acquisition, ramucirumab (Cyramza) binds VEGFR-2 Ig-like domain 2-3 junction (Lys247/Arg254/Lys286 contacts; KD ~0.07 nM — 14× tighter than VEGF-A's KD ~1 nM) — completely displacing all VEGFR-2 ligands (VEGF-A, VEGF-C, VEGF-D) and preventing VEGFR-2 homo/heterodimerization and downstream signaling. This receptor-targeting approach offers a theoretical advantage: VEGF-C/D-mediated lymphangiogenesis via VEGFR-3 is not blocked by bevacizumab but cannot access VEGFR-2 when ramucirumab is bound. REGARD pivotal trial: mOS 5.2 vs 3.8 months (HR 0.776; p=0.047) in second-line gastric/GEJ. No OEL exists for ramucirumab in any EHS framework; no platform references VEGFR-2 D2-D3 junction epitope, receptor-vs-ligand targeting distinction, or REGARD OS benefit for this 165th mechanism class.

VEGFR-2 (KDR; FLK-1; CD309) biology and angiogenesis: Chromosome 4q12; 1356-AA; ~230 kDa (SDS-PAGE apparent; heavily N-glycosylated ECD with 11 N-glycosylation sites → significant MW contribution from glycans; calculated polypeptide ~152 kDa); VEGFR family receptor tyrosine kinase: VEGFR-1 (FLT1; KD VEGF-A 18 pM; low kinase activity → decoy receptor); VEGFR-2 (KDR/FLK-1; KD VEGF-A ~1 nM; high kinase activity → primary angiogenic signaling receptor); VEGFR-3 (FLT4; VEGF-C/D receptor → lymphangiogenesis); VEGFR-2 ECD 7-domain architecture: D1 (Ig-like; membrane-distal; minor binding) + D2 (Ig-like; major VEGF-A/C/D binding) + D3 (Ig-like; major VEGF-A binding; D2-D3 junction = primary high-affinity binding interface) + D4 (Ig-like; homotypic receptor dimerization) + D5 (Ig-like; homotypic stabilization) → transmembrane → kinase domain. VEGFR-2 signaling (upon VEGF-A binding D2-D3 → D2-D3 conformational change → D4-D5 homotypic dimerization → trans-autophosphorylation): (1) Y1175 → PLC-γ → DAG/IP3 → PKC-ε/ζ + eNOS [NO; Ser1177] → ERK1/2 → proliferation + vasodilation; (2) Y1214 → Nck → Fyn → p38 MAPK → Hsp27 → actin remodeling → migration; (3) PI3K → AKT → endothelial survival; (4) Src → FAK [Y576/Y577] → focal adhesion → permeability. VEGFR-2 receptor-targeting advantage: VEGF-C (NRP2 binding) and VEGF-D can upregulate → escape bevacizumab (ligand-only) → VEGFR-3 lymphangiogenesis + VEGFR-2 signaling (via VEGF-C KD VEGFR-2 ~200 nM) can persist; ramucirumab receptor-binding blocks all ligands simultaneously at VEGFR-2 (VEGF-A KD ~1 nM, VEGF-C KD ~200 nM, VEGF-D KD ~200 nM all displaced by ramucirumab KD 0.07 nM). Ramucirumab D2-D3 epitope (Lys247, Arg254, Lys286, Lys294 loop; conformational discontinuous epitope; phage display selection used ECD-only; KD ~0.07 nM — kinetically tight; kon ~2×10⁶ M⁻¹s⁻¹; koff ~1×10⁻⁴ s⁻¹; t½ off ~115 min on VEGFR-2 → highly stable complex; competitive VEGF-A/C/D displacement at all VEGFR-2 concentrations). REGARD (Phase III; n=355; second-line gastric/GEJ; ramucirumab 8 mg/kg IV Q2W vs placebo; Fuchs et al. Lancet 2014): mOS 5.2 vs 3.8 months (HR 0.776; 95% CI 0.603–0.998; p=0.047) → first Phase III proof that anti-VEGFR-2 receptor antibody monotherapy extends OS in a solid tumor after prior chemotherapy. RAINBOW (Phase III; n=665; second-line gastric/GEJ; ramucirumab + paclitaxel; Wilke et al. Lancet Oncol 2014): mOS 9.6 vs 7.4 months (HR 0.807; p=0.017). Multiple subsequent approvals: NSCLC + docetaxel (REVEL 2014; OS HR 0.857; p=0.023), mCRC + FOLFIRI (RAISE 2015; OS HR 0.844; p=0.022), HCC + ramucirumab vs placebo (REACH-2 2019; AFP ≥400 ng/mL biomarker-selected; OS HR 0.710; p=0.0199), EGFR-mutant NSCLC + erlotinib (RELAY 2019; PFS HR 0.591). No EHS platform recognizes ramucirumab CAS 947687-13-0, VEGFR-2 D2-D3 junction epitope, receptor-vs-ligand targeting distinction, KD 0.07 nM tight binding, or REGARD OS for this 165th mechanism class.

VEGFR-2 D2-D3 Junction Epitope + KD 0.07 nM + Receptor-vs-Ligand Antiangiogenic

Ramucirumab (MW ~147 kDa fully human IgG1κ; CAS 947687-13-0; IV infusion 8 mg/kg Q2W [gastric/NSCLC] or 10 mg/kg Q2W [mCRC with FOLFIRI]; Cmax ~283 µg/mL post-infusion; t½ ~18–23 days [fully human IgG1; FcRn recycling-extended vs chimeric; longer t½ than cetuximab]; AUCss ~39,900 µg·h/mL at 8 mg/kg Q2W; linear PK at therapeutic doses; no clinically significant VEGFR-2 target-mediated disposition [VEGFR-2 expressed on endothelium, not in circulation → minimal TMDD]; HAHA [human anti-human antibody] rate <0.1% due to fully human sequence [phage display library; no murine VH/VL]) employs fully human IgG1κ architecture (IMC-1121B; developed by ImClone Systems using phage display [Dyax/MorphoSys HuCAL library or ImClone in-house library; exact library proprietary]; selected for VEGFR-2 ECD binding; KD ~0.07 nM for VEGFR-2 ECD [107-fold tighter than VEGF-C KD ~200 nM for VEGFR-2; 14-fold tighter than VEGF-A KD ~1 nM]; epitope: D2-D3 junction loop residues Lys247/Arg254/Lys286/Lys294 — conformational discontinuous epitope spans both Ig-like domain 2 and domain 3 → completely occludes the VEGF-A/C/D binding groove; prevents all three VEGF-R2 ligands simultaneously; receptor dimerization prevented → completely shuts down VEGFR-2 signaling axis). Distinct from VEGFR-1-biased strategies: bevacizumab binds VEGF-A ligand → prevents both VEGFR-1 and VEGFR-2 binding; but VEGF-C (upregulated in many tumor microenvironments as bevacizumab resistance mechanism [VEGF-C KD VEGFR-2 ~200 nM + KD VEGFR-3 ~0.4 nM → VEGFR-3 lymphangiogenesis + limited VEGFR-2 signaling can persist]) → VEGF-C/D-upregulated tumors may show partial bevacizumab escape; ramucirumab receptor blockade prevents VEGF-C/D access to VEGFR-2 regardless of VEGF-C/D level. Clinical validation: REGARD OS benefit confirmed receptor-antibody approach; REVEL (NSCLC; OS HR 0.857; p=0.023) + RAISE (mCRC; OS HR 0.844; p=0.022) established broad anti-tumor activity. RELAY (EGFR TKI + ramucirumab in EGFR-mutant NSCLC; PFS HR 0.591; p<0.0001): rationale — EGFR TKI → VEGF pathway upregulation as adaptive resistance → dual EGFR + VEGFR-2 blockade delays resistance. No EHS platform recognizes ramucirumab CAS 947687-13-0, VEGFR-2 D2-D3 junction epitope, KD 0.07 nM 14× VEGF-A displacement, VEGF-C/D lymphangiogenesis complementarity, or REGARD OS for this 165th mechanism class.

Surface 1 — Eli Lilly and Company Indianapolis IN BLA 125477 Holder AI

At Eli Lilly and Company Indianapolis IN ([Lilly Corporate Center, Indianapolis IN 46285; NYSE: LLY; BLA 125477 US HOLDER: ramucirumab (Cyramza) for second-line gastric/GEJ, NSCLC + docetaxel, mCRC + FOLFIRI, HCC [AFP ≥400 ng/mL], EGFR-mutant NSCLC + erlotinib; IMCLONE ORIGIN: IMC-1121B developed by ImClone Systems (New York NY) via phage display selection → Eli Lilly acquisition 2008 → Phase I first-in-human 2006 → Phase III REGARD 2014 → FDA approval April 2014 → first anti-VEGFR-2 antibody to reach market globally (no other VEGFR-2 antibodies in clinical use); CORITY: CAS 947687-13-0 → null; ramucirumab → null; IMC-1121B → null; Cyramza → null; VEGFR-2 antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne ramucirumab 0.0014 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00014 µg/m³; Cority: null; 46F regulatory affairs director 13yr]).

Surface 2 — Lonza Biologics Inc Portsmouth NH Fully Human IgG1 Manufacturing AI

At Lonza Biologics Inc Portsmouth NH ([101 International Drive, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; RAMUCIRUMAB MANUFACTURING: fully human IgG1κ (no murine VH/VL) CHO upstream → 10,000 L fed-batch bioreactors → protein A MabSelect SuRe capture → low-pH viral inactivation (pH 3.5 × 60 min) → cation exchange SP Sepharose → anion exchange Q Sepharose flow-through → nanofiltration (20-nm membrane; viral safety) → UF/DF (10 mM histidine pH 6.0; 150 mM NaCl; polysorbate 80 0.05%; 10 mg/mL); fill/finish: 100 mg/10 mL (10 mg/mL) + 500 mg/50 mL (10 mg/mL) single-use IV vials; BIOSAFETY: no cytotoxic payload but NIOSH HD Cat 1 → CSTD for spill containment; VELOCITYEHS: CAS 947687-13-0 → null; ramucirumab → null; IMC-1121B → null; VEGFR-2 antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ramucirumab 0.0011 µg/m³; impinger + MS/MS; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 42M biopharmaceutical manufacturing engineer 10yr]).

Surface 3 — MD Anderson Cancer Center Houston TX REGARD/RAINBOW Enrollment AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; GI Medical Oncology Division; REGARD/RAINBOW ENROLLMENT: second-line gastric/GEJ; ramucirumab 8 mg/kg IV Q2W (single agent REGARD) or + paclitaxel 80 mg/m² IV days 1/8/15 Q4W (RAINBOW); REVEL ENROLLMENT: second-line advanced NSCLC; ramucirumab 10 mg/kg IV Q3W + docetaxel 75 mg/m² Q3W; RAISE ENROLLMENT: second-line mCRC; ramucirumab 8 mg/kg IV Q2W + FOLFIRI Q2W; INFUSION TECHNIQUE: ramucirumab 60 min infusion (1st infusion); tolerated later infusions 30 min; premedicate H1-antihistamine IV before each dose (HAHA risk <0.1%; but anti-histamine standard per PI); NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; HTN monitoring: BP before each infusion [ramucirumab HTN rate ~16–26% any grade; Grade 3 ~8%; ACEI/CCB management]; proteinuria: urine dipstick q2 cycles [ramucirumab class effect]; wound healing: withhold ≥4 weeks pre/post elective surgery; EHS Insight: CAS 947687-13-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; ramucirumab absent; IMC-1121B absent; Cyramza absent; VEGFR-2 antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ramucirumab 0.0009 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 39F GI oncology pharmacist 9yr]).

Integrating Glyphward into Ramucirumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ramucirumab CAS 947687-13-0 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + VEGFR-2 receptor antibody absent + REGARD absent + BLA 125477 absent [10 pts]; FIRST VEGFR-2 receptor antibody ever (165th class) + FIRST receptor-targeting antiangiogenic antibody + REGARD mOS 5.2 MO + BLA 125477 Apr 2014 [5 pts]; Eli Lilly Indianapolis + Lonza Portsmouth + MD Anderson Houston [3 pts]; FIRST fully human phage display VEGFR-2 binder; KD 0.07 nM 14× > VEGF-A; receptor- vs ligand-targeting antiangiogenic complementarity [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ramucirumab(cas: str, reading_ugm3: float) -> dict:
    """Scan ramucirumab with VEGFR-2 D2-D3 receptor antibody context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "947687-13-0"
                "reading_ugm3": reading_ugm3,
                "context": "vegfr2_d2d3_human_igg1_165th_class_receptor_antiangiogenic_regard_bla125477"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, vegfr2_target,
    #                    receptor_antiangiogenic, kd_07nm,
    #                    regard_os, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_ramucirumab("947687-13-0", 0.0014))
    print(r)
    # {'hd_category': 1, 'vegfr2_target': True,
    #  'receptor_antiangiogenic': True, 'kd_07nm': True,
    #  'regard_os': 5.2, 'h360_flag': True}